Piper Sandler analyst Do Kim lowered the firm’s price target on TCR2 Therapeutics to $8 from $16 and keeps an Overweight rating on the shares as he pushed out gavo-cel estimates based on a revised clinical timeline due to the pace of development. The Phase 1 dose escalation trial continues to enroll and he expects an update from the Phase 2 portion of gavo-cel Phase 1/2 in the next 12 months, but the "timing is uncertain," Kim tells investors after the company reported Q3 results and issued its associated updates.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TCRR:
- TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
- TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today
- TCR2 Therapeutics’ gavo-cel shows benefit in solid tumor trials
- gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma